In addition, the most common adverse events in the ICIs combined with anti-angiogenic and chemotherapy therapy group were anemia (57.9%), nausea and vomiting (47.4%), and thyroid dysfunction (47.4%), while the grade 3 adverse events included neutropenia (5.3%), leukopenia (5.3%), anemia (5.3%), ALT increases (5.3%), and AST increases (5.3%) (Table 3). The gene discussed is GPT; the disease is neutropenia.